rosiglitazone has been researched along with uric acid in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altuntas, Y; Basat, O; Seber, S; Ucak, S | 1 |
| Javashvili, L; Kilasonia, L; Tananashvili, D; Tetradze, L; Virsaladze, D | 1 |
| Desch, S; Niebauer, J; Rastan, A; Schmidt, A; Schuler, G; Sixt, S; Sonnabend, M | 1 |
| Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Dzanković, F; Macić-Dzanković, A; Pojskić, B; Velija-Asimi, Z | 1 |
| Czechowska, G; Dudka, J; Korolczuk, A; Maciejewski, M; Smolen, A; Widelska, I | 1 |
4 trial(s) available for rosiglitazone and uric acid
| Article | Year |
|---|---|
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipid Metabolism; Middle Aged; PPAR alpha; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides; Uric Acid | 2006 |
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].
Topics: Adult; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Rosiglitazone; Thiazolidinediones; Uric Acid | 2007 |
Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease.
Topics: Aged; Blood Flow Velocity; Coronary Artery Disease; Endothelium, Vascular; Exercise Therapy; Exercise Tolerance; Female; Forearm; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Prediabetic State; Rosiglitazone; Thiazolidinediones; Uric Acid; Vasodilation | 2008 |
Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.
Topics: Biomarkers; C-Reactive Protein; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Uric Acid | 2009 |
3 other study(ies) available for rosiglitazone and uric acid
| Article | Year |
|---|---|
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Knee Joint; Male; Obesity; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Purines; Rats; Rats, Inbred OLETF; Risk Factors; Rosiglitazone; Thiazolidinediones; Uric Acid | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
The role of peroxisome-proliferator-activating receptor gamma agonists: rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 in chronic experimental cyclosporine A-induced nephrotoxicity.
Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Glutathione; Glutathione Disulfide; Kidney; Kidney Diseases; Male; NAD; NADP; PPAR gamma; Prostaglandin D2; Protective Agents; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Urea; Uric Acid | 2014 |